Log in
Enquire now
‌

US Patent 8008267 Stabilized immunomodulatory oligonucleotides

Patent 8008267 was granted and assigned to Idera Pharmaceuticals on August, 2011 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Idera Pharmaceuticals
Idera Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
8008267
Date of Patent
August 30, 2011
Patent Application Number
10865245
Date Filed
June 10, 2004
Patent Citations Received
‌
US Patent 11696954 Synthesis of spherical nucleic acids using lipophilic moieties
0
‌
US Patent 11957788 Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
0
Patent Primary Examiner
‌
Nita M. Minnifield
Patent abstract

The invention provides immunostimulatory oligonucleotides having at least one CpG dinucleotide and a secondary structure at the 5′- or 3′-end. These oligonucleotides have either reduced or improved immunostimulatory properties. The invention establishes that 5′-terminal secondary structures affect immunostimulatory activity significantly more than those at the 3′-end. The invention also provides methods for increasing or decreasing the immunostimulatory activity of a CpG-containing nucleic acid.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8008267 Stabilized immunomodulatory oligonucleotides

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.